NAMSNewAmsterdam Pharma Company N.V.

HealthcareUSD
$27.41

Price

$27.41+19%1Y
1M-10%1Y+19%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Below average
3/10
Value32
Quality36
Momentum59
Growth37
Strongest Momentum, weakest Value · ranked vs Healthcare peers. The five questions below judge the company on its own terms.
What they do

We are a late-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well tolerated and convenient low-density lipoprotein cholesterol (“LDL-C”) lowering therapy.

In the company’s own words · 10-K filed Feb 18, 2026 · SEC EDGAR

P/E (TTM)-
Market Cap$3.49B
1Y Return+19%
5Y Return+183%

NewAmsterdam Pharma Company N.V. (NAMS) reported revenue of $3.0M in Q1 2026 (quarter ended March 31, 2026), up 2.1% from the same quarter a year earlier. That came with net loss of $48M. For the full year FY2025, revenue was $23M (−51% year on year) and net income −$204M.

Raw charts

8 series · TTM

As reported to the SEC, without any scoring.

Biotechnology

Ranks #133 of 145 by Smart Score

Compare peers
CRNX-3.3%
Crinetics Pharmaceuticals, Inc.
TLX-0.37%
Telix Pharmaceuticals Limited
RCUS+5.0%
Arcus Biosciences, Inc.
RLAY-1.1%
Relay Therapeutics, Inc.
ELVN+2.8%
Enliven Therapeutics, Inc.
DNLI-0.36%
Denali Therapeutics Inc.